MELODIOL GLOBAL HEALTH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.003 AUD | -25.00% |
|
-33.33% | -92.50% |
| 04-16 | Melodiol Global's Revenue Surges 79% in Q1 | MT |
| 04-09 | Melodiol Global Health Subsidiary Health House Australia to Launch Medicinal Cannabis Clinic | MT |
| Sales 2022 | 8.92M 5.83M 466M | Sales 2023 | 18.92M 12.36M 989M | Capitalization | 9.46M 6.18M 495M |
|---|---|---|---|---|---|
| Net income 2022 | -32M -20.9M -1.67B | Net income 2023 | -52M -33.97M -2.72B | EV / Sales 2022 | 4.71 x |
| Net Debt 2022 | 5.28M 3.45M 276M | Net Debt 2023 | 8.95M 5.85M 468M | EV / Sales 2023 | 0.97 x |
| P/E ratio 2022 |
-0.89
x | P/E ratio 2023 |
-0.11
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.01% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -25.00% | ||
| 1 week | -33.33% | ||
| Current month | -40.00% | ||
| 1 month | -25.00% | ||
| 3 months | -86.36% | ||
| 6 months | -96.25% | ||
| Current year | -92.50% |
1 week
0.00
0.01
1 month
0.000.01
Current year
0.000.04
1 year
0.000.44
3 years
0.004.40
5 years
0.0011.50
10 years
0.0033.00
| Managers | Title | Age | Since |
|---|---|---|---|
William Lay
CEO | Chief Executive Officer | - | 16/09/21 |
Chris Grundy
DFI | Director of Finance/CFO | - | 20/11/17 |
John Griese
COO | Chief Operating Officer | 38 | 13/06/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bruce Linton
BRD | Director/Board Member | 57 | 16/01/22 |
Peter Hatfull
BRD | Director/Board Member | 71 | 29/11/22 |
Boaz Wachtel
FOU | Founder | - | 19/11/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.003 | -25.00% | 1,500,247 |
| 24/04/24 | 0.004 | 0.00% | 2,130,048 |
| 23/04/24 | 0.004 | -20.00% | 88,631,000 |
| 22/04/24 | 0.005 | +11.11% | 695,182 |
| 19/04/24 | 0.0045 | +12.50% | 48,653 |
Delayed Quote Australian S.E., April 26, 2024 at 07:10 am
More quotes
Melodiol Global Health Limited, formerly Creso Pharma Limited, is an Australia-based cannabis company. The Company is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. It cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc., it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.
Sector
Pharmaceuticals
Calendar
30/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -92.50% | 1.32M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ME1 Stock
